Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-23

Clinical Trial Update: Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial of GSK2402968 for Duchenne muscular dystrophy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GSK2402968

Snippet

Sponsor: GlaxoSmithKline | Conditions: Muscular Dystrophies | Phase 3 | Status: TERMINATED